Dr. Biran Discusses Doublets Versus Triplets in Myeloma

Video

In Partnership With:

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Biran says that in the newly diagnosed setting, triplet therapy is better than doublet therapy, both in the transplant-eligible and transplant-ineligible patients. Triplets have shown very rapid and deep responses in these patients, which usually translates into a longer duration of remission, explains Biran.

The SWOG S0777 trial, which evaluated bortezomib (Velcade) with lenalidomide (Revlimid) and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant, showed a longer progression-free survival and overall survival in patients who received the triplet. Biran says that these findings show that it is important to keep those who are ineligible for transplant on a triplet regimen.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Lori A. Leslie, MD, an expert on lymphoma